Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
BI 1361849: A self-adjuvanting mRNA-based Immunotherapeutic Cancer Vaccine
BI 1361849* (CV9202) is an mRNA-based immunotherapeutic cancer vaccine (ICV) that has the potential to mobilise the patient’s immune system to fight tumours. It is currently being investigated in non-small cell lung cancer (NSCLC) following promising preclinical results.1
About BI 1361849
BI 1361849’s mechanism of action
BI 1361849 (CV9202) is an mRNA-based ICV created using RNActive® (CureVac AG, Germany) technology, which utilises optimised mRNA sequences to increase antigen expression.2,3 BI 1361849 consists of six mRNAs that code for six different antigens that are frequently expressed in NSCLC:
Vaccines created using RNActive® technology have two components:
The mechanism of action of BI 1361849 is thought to be as follows:2,11,12
Clinical development: NSCLC
CV9201-003, a Phase I/IIa trial with a BI 1361849 predecessor, demonstrated that antigen-specific responses against at least one antigen occurred in 65% of patients receiving CV9201; cellular and humoral immune responses were detected in 39% and 49% of these patients, respectively.13 In a Phase Ib study, CV9202-006, cellular and humoral immune responses were elicited in the majority of patients and 52% of evaluable NSCLC patients had stable disease.14,15
BI 1361849 is currently being investigated in combination with durvalumab and tremelimumab in a Phase I/II trial in NSCLC patients.14 Future trials are being planned to investigate BI 1361849 in combination with other immunotherapies.
AE, adverse event; DoR, duration of response; ICV, immunotherapeutic cancer vaccine; mRNA, messenger ribonucleic acid; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
Hipp MM, et al. Cancer Immunol Res 2016;4(Suppl. 11):B072
CureVac AG. RNActive® cancer immunotherapies and prophylactic vaccine. http://www.curevac.com/rna-platform/rnactiver/ (Accessed: July 2017).
Sebastian M, et al. BMC Cancer 2014;14:748.
Kim SH, et al. Lung 2009;187(6):401–11.
Cho HJ, et al. Cancer Immun 2006;6:12.
Chen X, et al. Oncol Lett 2017;13(3):1609–18.
Damelin M, et al. Cancer Res 2011;71(12):4236–46.
Zhang LQ, et al. PLoS ONE 2012;7(3):e34100.
Singh R, Bandyopadhyay D. Cancer Biol Ther 2007;6(4):481–6.
Kallen KJ, et al. Hum Vaccin Immunother 2013;9(10):2263–76.
Sebastian M, et al. J Clin Oncol 2012;30(15 Suppl):Abstract 2573.
Kowalczyk A, et al. Vaccine 2016;34(33):3882–93.
Sebastian M, et al. J Clin Oncol 2012;30(Suppl. 15):2573.
Hipp MM, et al. Cancer Immunol Res 2016;4(Suppl. 11):B072.
Papachristofilou A, et al. J Thorac Oncol 2017;12(Suppl. 1):S1333–S1334.
ClinicalTrials.gov. NCT03164772. https://clinicaltrials.gov/ct2/show/NCT03164772 (Accessed: September 2018).
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: October 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue